{"id":47,"date":"2014-07-31T11:10:10","date_gmt":"2014-07-31T15:10:10","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=47"},"modified":"2014-09-10T15:07:37","modified_gmt":"2014-09-10T19:07:37","slug":"duane-morris-partner-frederick-ball-to-moderate-at-the-fdlis-conference-celebrating-the-30th-anniversary-of-the-hatch-waxman-amendments-the-past-present-and-future-of-generic-drugs","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2014\/07\/31\/duane-morris-partner-frederick-ball-to-moderate-at-the-fdlis-conference-celebrating-the-30th-anniversary-of-the-hatch-waxman-amendments-the-past-present-and-future-of-generic-drugs\/","title":{"rendered":"Duane Morris Partner Frederick Ball to Moderate at the FDLI&#8217;s Conference, Celebrating the 30th Anniversary of the Hatch-Waxman Amendments: The Past, Present and Future of Generic Drugs"},"content":{"rendered":"<p>Duane Morris partner <a href=\"http:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\" target=\"_blank\">Frederick R. Ball<\/a> will be serving as a moderator on a session titled &#8220;The Present Part 2: Generic Industry Challenges and Current Issues&#8221; at the Food and Drug Law Institute&#8217;s conference. The conference, <a href=\"http:\/\/www.fdli.org\/conferences\/conference-pages\/generic-drugs\/general-information\" target=\"_blank\">Celebrating the 30th Anniversary of the Hatch-Waxman Amendments: The Past, Present and Future of Generic Drugs<\/a>, will take place on September 18, 2014 in Washington, D.C. Mr. Ball&#8217;s session will begin at 1:45 p.m.<\/p>\n<p><!--more--><\/p>\n<p><strong>About the Conference<\/strong><\/p>\n<p>This year marks the 30th Anniversary of the Hatch-Waxman Amendments, which were enacted to promote generics while keeping financial incentives for research and development for brand manufacturers. Join us for this timely a one-day conference that explores why the Act was passed, where we are right now in terms of FDA and industry developments, and what&#8217;s on the horizon in terms of ongoing brand-generic issues Speakers from Capitol Hill, FDA, the private bar and industry will provide practical insights on the impact of the Hatch-Waxman Amendments, controversial issues currently facing generic drug manufacturers and their counsel. Don&#8217;t miss out on this historic event.<\/p>\n<p>For more information or to register, please visit the <a href=\"http:\/\/www.fdli.org\/conferences\/conference-pages\/generic-drugs\/general-information\" target=\"_blank\">FDLI website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duane Morris partner Frederick R. Ball will be serving as a moderator on a session titled &#8220;The Present Part 2: Generic Industry Challenges and Current Issues&#8221; at the Food and Drug Law Institute&#8217;s conference. The conference, Celebrating the 30th Anniversary of the Hatch-Waxman Amendments: The Past, Present and Future of Generic Drugs, will take place &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2014\/07\/31\/duane-morris-partner-frederick-ball-to-moderate-at-the-fdlis-conference-celebrating-the-30th-anniversary-of-the-hatch-waxman-amendments-the-past-present-and-future-of-generic-drugs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Duane Morris Partner Frederick Ball to Moderate at the FDLI&#8217;s Conference, Celebrating the 30th Anniversary of the Hatch-Waxman Amendments: The Past, Present and Future of Generic Drugs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[121,122,123,40,119],"ppma_author":[521],"class_list":["post-47","post","type-post","status-publish","format-standard","hentry","category-general","tag-fdli","tag-food-and-drug-law-institute","tag-generics","tag-hatch-waxman","tag-rick-ball"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","author_category":"1","last_name":"Sullivan","first_name":"Margaret","job_title":"","user_url":"http:\/\/www.duanemorris.com","description":"<a href=\"http:\/\/www.duanemorris.com\">Visit the Duane Morris website.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/47","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=47"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/47\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=47"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=47"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=47"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=47"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}